HC Wainwright Predicts Reduced Earnings for Gossamer Bio

Gossamer Bio, Inc. (NASDAQ:GOSS) – Analysts at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for Gossamer Bio in a report issued on Tuesday, March 18th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.16) per share for the quarter, down from their previous forecast of ($0.15). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Gossamer Bio’s Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.56) EPS and FY2027 earnings at ($0.04) EPS.

Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.15) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.15). The firm had revenue of $9.38 million for the quarter, compared to analyst estimates of $7.02 million.

Separately, Wedbush reiterated an “outperform” rating and set a $4.00 price objective on shares of Gossamer Bio in a research note on Friday, March 14th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $9.20.

Gossamer Bio Stock Up 3.0 %

Shares of NASDAQ:GOSS opened at $1.39 on Thursday. The company’s fifty day moving average is $1.16 and its two-hundred day moving average is $0.98. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74. Gossamer Bio has a 1-year low of $0.50 and a 1-year high of $1.55. The stock has a market capitalization of $315.84 million, a price-to-earnings ratio of -4.34 and a beta of 1.86.

Institutional Investors Weigh In On Gossamer Bio

A number of hedge funds have recently added to or reduced their stakes in the stock. Graham Capital Management L.P. acquired a new stake in shares of Gossamer Bio in the 4th quarter worth about $32,000. Fullcircle Wealth LLC bought a new position in Gossamer Bio in the 4th quarter worth about $43,000. GSA Capital Partners LLP acquired a new stake in shares of Gossamer Bio in the third quarter valued at approximately $67,000. Velan Capital Investment Management LP acquired a new position in shares of Gossamer Bio during the fourth quarter worth approximately $68,000. Finally, Bank of America Corp DE boosted its position in shares of Gossamer Bio by 107.2% during the fourth quarter. Bank of America Corp DE now owns 84,788 shares of the company’s stock worth $77,000 after buying an additional 43,866 shares during the period. 81.23% of the stock is currently owned by institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.